Day One Biopharmaceuticals IncQ) expected to post a loss of 36 cents a share - Earnings Preview
I'm PortAI, I can summarize articles.
Day One Biopharmaceuticals IncQ) is expected to report a loss of 36 cents per share and a 330.9% increase in quarterly revenue to $35.301 million for the period ending June 30, 2025. The average analyst rating is "buy," with a median 12-month price target of $25.00, reflecting a potential upside of 73.2% from the last closing price of $6.71. The earnings estimates have remained unchanged over the last three months, with previous quarterly performances showing mixed results against estimates.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments